• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Lundbeck joins Global Alzheimer’s Platform

Lundbeck joins Global Alzheimer’s Platform

August 10, 2015
CenterWatch Staff

Lundbeck, a global pharmaceutical company specializing in brain disorders, has joined the Global Alzheimer’s Platform (GAP) to help accelerate the development of new treatments for Alzheimer’s disease. GAP is a research initiative that aims to reduce the time and costs of Alzheimer’s disease clinical trials, develop an infrastructure that promotes innovation, and assure international collaboration on Alzheimer’s disease treatments.

Led by the Global CEO Initiative on Alzheimer’s Disease (CEOi) and the New York Academy of Sciences, GAP is driven through collaboration among pharmaceutical companies, academic institutions, nonprofit patient advocacy organizations and public funding. As Lundbeck develops new treatments for people living with Alzheimer’s disease, GAP’s efforts will be particularly impactful.

“Lundbeck’s engagement in the leadership of the GAP Initiative greatly strengthens our efforts to bring private, public and academic leaders together to accelerate the development and delivery of innovative Alzheimer’s treatments to those with or at risk for this disease,”  said George Vradenburg, chairman and chief executive officer of GAP.

GAP is establishing a global, standing, trial-ready platform that may decrease clinical testing cycle times by two years or more and should reduce costs. The platform would promote efficiency and uniformity in trial populations through large, well-characterized, trial-ready cohorts, certified clinical trial sites and an adaptive proof-of-concept trial mechanism.

Lundbeck currently has three compounds in development, including two phase III investigational therapies to address symptoms of Alzheimer’s disease and a phase I vaccine candidate to potentially slow disease progression.

According to Alzheimer’s Disease International, the disease is estimated to affect 5.4 million people in the U.S. and nearly 44 million people worldwide. The prevalence of Alzheimer’s is projected to reach 135 million by 2050.

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing